Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmaco-Scintigraphic Study of Metronidazole Benzoate Capsules in Healthy Subjects
NCT02911298Phase 1Completed
- Sponsor
- Tillotts Pharma AG
- Start
- Nov 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of metronidazole benzoate in anaerobic infection, protozoan infection and Clostridioides difficile infection (CDI) (2 arms), sponsored by Tillotts Pharma AG. Primary endpoints: Scintigraphic analysis of time of capsule disintegration at 3 days, Scintigraphic analysis of location of capsule disintegration at 3 days and 1 more. Started Nov 2016; status: completed.
02
Drugs
metronidazole benzoate
03
Conditions
anaerobic infectionprotozoan infectionClostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02911298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911298.